ORPHEUS
OFFICIAL TITLE: A MULTICENTER, OPEN-LABEL, SINGLE-ARM, PHASE II CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF INCMGA00012 IN ADVANCED PENILE SQUAMOUS CELL CARCINOMA – ORPHEUS
PRESS RELEASE
SCIENTIFIC IMPACT
ASCO 2023: - DOWNLOAD THE POSTER
ASCO 2023: - DOWNLOAD THE LAY LANGUAGE SUMMARY
ASCO GU 2022: - DOWNLOAD THE POSTER
BLOG ARTICLES RELATED
TRIAL RESUME
ORPHEUS SITES
SPAIN
ICO L'Hospitalet. Catalan Institute of Oncology
SPAIN
Hospital Insular de Gran Canaria
SPAIN
Hospital Virgen de la Arrixaca
SPAIN
Hospital Virgen del Rocío
SPAIN
Hospital Miguel Servet
SPAIN
Instituto Valenciano de Oncología
SPAIN
Hospital de la Santa Creu i Sant Pau
SPAIN
Hospital Universitario Doce de Octubre
SPAIN
Hospital Clínico San Carlos
SPAIN
Hospital Universitari Son Espases
ITALY
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
ITALY
AUSL Reggio Emilia
ITALY
Ospedale San Raffaele
CLINICAL TRIAL DETAILS
ORPHEUS IS AN INTERNATIONAL, MULTICENTER, OPEN-LABEL, SINGLE-ARM, PHASE II CLINICAL TRIAL IN MEN WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PENILE SQUAMOUS CELL CARCINOMA (PSCC).
THE PRIMARY GOAL IS TO ASSESS THE EFFICACY –AS DETERMINED BY THE OBJECTIVE RESPONSE RATE (ORR)– OF INCMGA00012 IN THE STUDY POPULATION.
IN ADDITION, THIS STUDY WILL ALSO EVALUATE THE SAFETY AND TOLERABILITY OF INCMGA00012 IN THESE PATIENTS.
TUMOR TYPE
PHASE
PENILE
II
18
13
Spain, Italy
N
SITES
COUNTRY
STATUS
Closing